Skip to main content

Advertisement

SpringerLink
Log in

Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications

  • Short Communication
  • Published:
International Journal of Peptide Research and Therapeutics Aims and scope Submit manuscript

Abstract

Protein phosphatase 2A (PP2A) is known to be a negative regulator of several survival and proliferating pathways that are frequently altered in cancer. In addition to chemical enzymatic inhibitors of the PP2A activity, the oncoprotein SET has been described as a physiological PP2A inhibitor by forming a complex with PP2A catalytic subunit (PP2Ac). Increased SET protein levels therefore directly reduce the tumor suppressor function of PP2A and promote tumor progression. We have used the PEP-Scan approach to identify the binding site between the serine/threonine phosphatase PP2A and the oncoprotein SET. For in vivo validation of the peptides, we have used chronic lymphocytic leukemia (CLL) xenograft models. In this manuscript we describe the identification of amino acid sequences involved in the complex formation, both at the PP2Ac and SET sides. The amino acid sequences of the binding sites were coupled to an optimized penetrating peptide in order to generate chimeras (Mut3DPT-PP2A and Mut3DPT-SET) able to target the PP2A/SET interaction. We demonstrate that these peptides have an in vitro apoptotic effect on breast and lung cancer cell lines, as well as an antitumoral effect on CLL and lymphoma xenograft models. The new generated chimeric peptides allow the modulation of the PP2Ac/SET interaction and might have a potential as a new therapeutic approach for cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  • Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 20:2092–2103

    Article  CAS  PubMed Central  Google Scholar 

  • Arrouss I, Nemati F, Roncal F, Wislez M, Dorgham K, Vallerand D, Rabbe N, Karboul N, Carlotti F, Bravo J et al (2013) Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy. PloS ONE 8:e60816

    Article  CAS  PubMed Central  Google Scholar 

  • Arrouss I, Decaudin D, Choquet S, Azar N, Parizot C, Zini JM, Nemati F, Rebollo A (2015) Cell penetrating peptides as a therapeutic strategy in chronic lymphocytic leukemia. Protein Pept Lett 22(6):539–546

    Article  CAS  Google Scholar 

  • Chen L, Luo LF, Lu J, Li L, Liu YF, Wang J, Liu H, Song H, Jiang H, Chen SJ et al (2014) FTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. PloS ONE 9:e103033

    Article  PubMed Central  Google Scholar 

  • Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, Volkheimer AD, Lanasa MC, Friedman DR, Goodman BK et al (2011a) SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 118:4150–4158

    Article  CAS  PubMed Central  Google Scholar 

  • Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li F, Colton CA, Vitek MP (2011b) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186:2535–2542

    Article  CAS  Google Scholar 

  • Ciccone M, Calin GA, Perrotti D (2015). From the biology of PP2A to the PADs for therapy of hematologic malignancies. Front Oncol 5:21

    Article  PubMed Central  Google Scholar 

  • Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ, Odero MD (2012) Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97:543–550

    Article  CAS  PubMed Central  Google Scholar 

  • de Figueiredo IR, Freire JM, Flores L, Veiga AS, Castanho MA (2014) Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies. IUBMB Life. doi:10.1002/iub.1257

    Article  PubMed  Google Scholar 

  • Eichhorn PJ, Creyghton MP, Bernards R (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795:1–15

    PubMed  CAS  Google Scholar 

  • Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP (1996) Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. Curr Biol 6:84–91

    Article  CAS  Google Scholar 

  • Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C et al. (2014) Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res 12:924–939

    Article  CAS  PubMed Central  Google Scholar 

  • Fominaya J, Bravo J, Decaudin D, Brossa JY, Nemati F, Rebollo A (2015) Enhanced serum proteolysis resistance of cell-penetrating peptides. Ther Deliv 6:139–147

    Article  CAS  Google Scholar 

  • Frank R, Overwin H (1996). SPOT synthesis. Epitope analysis with arrays of synthetic peptides prepared on cellulose membranes. Methods Mol Biol 66:149–169

    PubMed  CAS  Google Scholar 

  • Gausepohl H, Boulin C, Kraft M, Frank RW (1992) Automated multiple peptide synthesis. Pept Res 5:315–320

    PubMed  CAS  Google Scholar 

  • Guergnon J, Dessauge F, Dominguez V, Viallet J, Bonnefoy S, Yuste VJ, Mercereau-Puijalon O, Cayla X, Rebollo A, Susin SA et al. (2006a) Use of penetrating peptides interacting with PP1/PP2A proteins as a general approach for a drug phosphatase technology. Mol Pharmacol 69:1115–1124

    Article  CAS  Google Scholar 

  • Guergnon J, Dessauge F, Traincard F, Cayla X, Rebollo A, Bost PE, Langsley G, Garcia A (2006b). A PKA survival pathway inhibited by DPT-PKI, a new specific cell permeable PKA inhibitor, is induced by T. annulata in parasitized B-lymphocytes. Apoptosis 11:1263–1273

    Article  CAS  Google Scholar 

  • Haesen D, Sents W, Lemaire K, Hoorne Y, Janssens V (2014). The basic biology of PP2A in hematologic cells and malignancies. Front Oncol 4:347

    Article  PubMed Central  Google Scholar 

  • Hahn WC, Weinberg RA (2002) Rules for making human tumor cells. N Engl J Med 347:1593–1603

    Article  CAS  Google Scholar 

  • Huang Y (2014) Cell-penetrating peptides and drug delivery. Curr Pharm Biotechnol 15:191

    Article  CAS  PubMed Central  Google Scholar 

  • Janssens V, Rebollo A (2012) The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med 12:268–287

    Article  CAS  PubMed Central  Google Scholar 

  • Janssens V, Goris J, Van Hoof C (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15:34–41

    Article  CAS  PubMed Central  Google Scholar 

  • Johansson HJ, El-Andaloussi S, Holm T, Mae M, Janes J, Maimets T, Langel U (2008). Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol Ther 16:115–123

    Article  CAS  Google Scholar 

  • Jones S, Holm T, Mager I, Langel U, Howl J (2010) Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. Chem Biol 17:735–744

    Article  CAS  Google Scholar 

  • Kalev P, Sablina AA (2011) Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 11:38–46

    Article  CAS  Google Scholar 

  • Lambrecht C, Haesen D, Sents W, Ivanova E, Janssens V (2013) Structure, regulation, and pharmacological modulation of PP2A phosphatases. Methods Mol Biol 1053:283–305

    Article  CAS  Google Scholar 

  • Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J, Curti C (2012) SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol 48:1106–1113

    Article  CAS  Google Scholar 

  • Li M, Guo H, Damuni Z (1995). Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34:1988–1996

    Article  CAS  Google Scholar 

  • Li M, Makkinje A, Damuni Z (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271:11059–11062

    Article  CAS  Google Scholar 

  • Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 138:1303–1312

    Article  CAS  PubMed Central  Google Scholar 

  • Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, Ogretmen B (2009). Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 23:751–763

    Article  CAS  PubMed Central  Google Scholar 

  • Neviani P, Perrotti D (2014). SETting OP449 into the PP2A-activating drug family. Clin Cancer Res 20:2026–2028

    Article  CAS  PubMed Central  Google Scholar 

  • Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM et al (2013) PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 123:4144–4157

    Article  CAS  PubMed Central  Google Scholar 

  • Pippa R, Dominguez A, Christensen DJ, Moreno-Miralles I, Blanco-Prieto MJ, Vitek MP, Odero MD (2014) Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28:1915–1918

    Article  CAS  Google Scholar 

  • Sablina AA, Hector M, Colpaert N, Hahn WC (2010) Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res 70:10474–10484

    Article  CAS  PubMed Central  Google Scholar 

  • Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G (2016) All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J 283:1004–1024

    Article  CAS  Google Scholar 

  • Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP (2011) Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30:2504–2513

    Article  CAS  PubMed Central  Google Scholar 

  • Vitek MP, Christensen DJ, Wilcock D, Davis J, Van Nostrand WE, Li FQ, Colton CA (2012) APOE-mimetic peptides reduce behavioral deficits, plaques and tangles in Alzheimer’s disease transgenics. Neuro-degenerative Dis 10:122–126

    Article  CAS  Google Scholar 

  • Westermarck J, Hahn WC (2008) Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 14:152–160

    Article  CAS  Google Scholar 

  • Yang Y, Huang Q, Lu Y, Li X, Huang S (2012) Reactivating PP2A by FTY720 as a novel therapy for AML with C-KIT tyrosine kinase domain mutation. J Cell Biochem 113:1314–1322

    Article  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Valerie Friser for help in the collection of the CLL samples. This work was supported by Inserm and SATT Lutech, the Belgian Foundation against Cancer (FAF-F/2016/822), the Fund for Scientific Research-Flanders (G.0B01.16N), the Belgian IAP Program (P7/13) and the KU Leuven (OT/13/094).

Author information

Author notes

  1. Lu Tian and Xiguang Zhang have contributed equally to this work.

Authors and Affiliations

  1. CIMI Paris, UPMC UMR CR7, Inserm U1135, CNRS ERL 8255, 91, bd de l’Hôpital, 75013, Paris, France

    Lu Tian, Xiguang Zhang, Jesus Fominaya & Angelita Rebollo

  2. Laboratory of Protein Phosphorylation and Proteomics, Department Cellular and Molecular Medicine, University of Leuven & Leuven Cancer Institute (LKI), 3000, Leuven, Belgium

    Dorien Haesen, Etienne Waelkens & Veerle Janssens

  3. IBV-CSIC, Instituto de Biomedicina de Valencia, c/ Jaime Roig 11, 46010, Valencia, Spain

    Jeronimo Bravo

  4. AH-HP, Hôpital La Pitié Salpêtrière, 43, bd de l’Hôpital, 75013, Paris, France

    Sylvain Choquet

  5. AP-HP, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010, Paris, France

    Jean Marc Zini

  6. Animalerie de l’UBO, UFR Médecine, 22 Avenue Camille Desmoulins, 29238, Brest, France

    Severine Loisel

Authors
  1. Lu Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiguang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dorien Haesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeronimo Bravo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jesus Fominaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sylvain Choquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean Marc Zini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Severine Loisel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Etienne Waelkens
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Veerle Janssens
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Angelita Rebollo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelita Rebollo.

Ethics declarations

Conflict of interest

Authors declare no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the National Ministry of Health and APHP committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Research Involving Human and Animal Participants

All mice were maintained under conditions and protocols in accordance with the Directive 2010/63/UE of the Council of Europe on Animal Welfare. The studies (number authorization 5220) were approved by the French Ethics Committee for animal experimentation number 74 and all experiments were conducted following the guidelines of the aforementioned committee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tian, L., Zhang, X., Haesen, D. et al. Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications. Int J Pept Res Ther 24, 479–488 (2018). https://doi.org/10.1007/s10989-017-9633-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10989-017-9633-1

Keywords

Search

Navigation